Recombinant antihemophilic factor plasma/albumin-free method: Phase II/III data; under review in EU, U.S., Canada and Switzerland

In an ongoing, open-label Phase II/III trial in 41 patients

Read the full 108 word article

How to gain access

Continue reading with a
two-week free trial.